Agilent Technologies Inc.. (1/10/12). "Press Release: Agilent Technologies and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-based Assays for Early Disease Detection".

	Organisation	Agilent Technologies Inc. (NYSE: A)
	Group	Agilent (Group)
	Organisation 2	Integrated Diagnostics Inc.
	Product	clinical mass spectrometry-based proteomic test
	Product 2	6490 Triple Quadrupole LC/MS system (Agilent)
	Index term	Agilent–Integrated Diagnostics: MS-based protoeomic assays, 201201– collab strategic partnership developm for early disease detection
	Index term 2	Integrated Diagnostics–Aglent: mass spectrometer, 201201 supply purchase of two 6490 iFunnel triple quad ms systems as part of collaboration
	Person	Kearney, Paul (Integrated Diagnostics 201201 CSO)
	Person 2	Salem, Gustavo (Agilent 201006 VP + General Manager Biological Systems Division 200802 VP + General Manager LC/MS Div)

Agilent Technologies Inc. (NYSE: A) and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

Integrated Diagnostics, an emerging leader in molecular diagnostics, is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect diseases such as lung cancer and Alzheimer's at their earliest stages. Agilent manufactures a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems. Officials of both organizations see an opportunity to rapidly turn medical breakthroughs into diagnostic assays by combining efforts to focus on protein and peptide biomarkers of disease.

"Agilent provides an innovative and forward-looking platform and expertise to enable the development and deployment of next-generation multiplexed proteomic assays," said Paul Kearney, Ph.D., president and chief scientific officer, Integrated Diagnostics. "Integrated Diagnostics will bring expertise in assay development, technology strategy, study design, clinical development, commercialization and systems informatics to leverage the Agilent technology solution. Together, we intend to realize the potential of clinical proteomics today as well as establish the technological platform and strategy for the field. Our partnership with Agilent will allow us to realize the advantages of using a single technology platform from discovery and verification through to commercialization."

"Agilent and Integrated Diagnostics share the vision of harnessing the power of an integrative systems biology approach to solving some of mankind's most vexing health challenges," said Gustavo Salem, vice president and general manager of the Biological Systems Division at Agilent. "It's very exciting to be at the forefront of helping technology migrate from the research lab to the clinic, in this case developing next-generation workflows to improve protein-based LC/MS assays."

As part of the partnership, Integrated Diagnostics purchased two Agilent 1290 Infinity UHPLC systems, two 6490 iFunnel triple quadrupole mass spectrometry systems and two 1260 LCs with ultraviolet detectors for the project.

The partnership will develop high-throughput automated workflows to include sample preparation and LC MS/MS analysis. Participants expect accelerated biomarker discovery to be fueled by novel sample-prep technology, fast liquid chromatography and ultra-sensitive ion funnel triple quadrupole mass spectrometry.

The technology opens the possibility of screening for several hundred biomarkers in a single assay, in a very high-throughput and quantitative fashion, according to Agilent.

About Integrated Diagnostics

Integrated Diagnostics is developing large-scale, blood-based molecular diagnostics that detect important diseases like lung cancer and Alzheimer's at their earliest stages by simultaneously monitoring tens to hundreds of disease markers. The company, founded in October 2009 by systems biology pioneer Dr. Lee Hood, is creating a new generation of personalized medical solutions using sophisticated informatics for biomarker selection and a novel class of synthetically created diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. Integrated Diagnostics' mission is to build a new generation of low-cost, large-scale diagnostic assays for early detection of serious diseases. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners, The Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems Biology and Caltech. Learn more at www.integrated-diagnostics.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company's 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Stuart Matlow, Agilent
+1 408 553 7191
stuart_matlow@agilent.com

Eliot Dobris, for Integrated Diagnostics
+1 415 902 1241
eliot@eliotdobris.com

Record changed: 2012-01-13

Follow Us!

Top News

Upcoming Events

Associations

Partners

Agilent Technologies Inc.. (1/10/12). "Press Release: Agilent Technologies and Integrated Diagnostics Enter Strategic Partnership to Develop Protein-based Assays for Early Disease Detection".

More documents for Agilent (Group)